R&D channel feed – Endpoints News

R&D channel feed

Aldeyra slides as lead drug flunks a primary endpoint in PhIIb

8 years ago

Jeffrey Kindler’s Centrexion spells out positive data for its PhIII-ready pain drug

8 years ago

Harvard researchers hope to bridge the protein gap with new institute

8 years ago

pSivida lines up EMA, FDA applications for eye drug/device as 2nd PhIII delivers positive data

8 years ago

J&J boasts improved cardio safety with SGLT2 franchise drug Invokana

8 years ago

Acceleron scraps dalantercept after it flunks a PhII test for kidney cancer

8 years ago

Merck halts enrollment on two PhIII Keytruda combo studies as outside monitors flag a worrying rate of deaths

8 years ago

AstraZeneca punts NASH drug from an ailing Regulus as their lead program goes under for the last time

8 years ago

Seres grabs $20M on PhIII microbiome launch

8 years ago

With an FDA decision looming, Flexion touts new data spotlighting a safety edge for osteoarthritis drug

8 years ago

Merck, Pfizer make their PhIII case for an SGLT2 latecomer to the blockbuster showdown in diabetes

8 years ago

Eli Lilly posts promising PhIII migraine results, but settles into the pack in the last leg of the race to the FDA

8 years ago

Trial observers say ‘game over’ for XBiotech's failed PhIII cancer study, the latest in a long line of setbacks

8 years ago

Merck cautiously steps into the PD-(L)1/CTLA-4 checkpoint fray. But should it ‘go big or go home’ instead?

8 years ago

Lexicon 3-for-3 in PhIII for a new diabetes pill, racking up a clean sweep under $1.7B Sanofi pact

8 years ago

Genentech axes its $1B-plus IDO drug deal with NewLink in the wake of underwhelming data

8 years ago

Actelion’s R&D group slammed with a setback as execs finalize $30B J&J deal

8 years ago

J&J woos Merck's Mathai Mammen to helm of pharma R&D, Hait takes over on external innovation

8 years ago

Novartis posts landmark CAR-T data as head-to-head rivalry with Kite Pharma looms

8 years ago

Teva turns the last corner in the CGRP migraine drug race with its 2nd round of promising PhIII data

8 years ago

AbbVie gets a big boost in the major league rheumatoid arthritis finals with promising PhIII data

8 years ago

July 12 FDA panel review looms as a watershed moment in Novartis’ campaign to win an historic new drug OK

8 years ago

ASCO17: Chi-Med spotlights positive colon cancer data as partner Eli Lilly preps landmark China rollout

8 years ago

ASCO17: AstraZeneca pumps up expectations on near-term cancer drug wins, looking to shed a rep for failure

8 years ago

First page Previous page 297 298 299300301 302 303 Next page Last page